Search
Tezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]
Sodium phosphate, dibasic
go.drugbank.com/drugs/DB14502ApprovedInvestigationalMixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Plantago seed
go.drugbank.com/drugs/DB11097ApprovedInvestigationalIt is found in some laxatives for treating occasional constipation and restoring regularity in bowel movements. … Its potential benefit in maintaining remission in ulcerative colitis has been studied [A27156].
Mixtures: Konsyl Overnight Relief Senna PromptMagnesium oxide
go.drugbank.com/drugs/DB01377ApprovedInvestigationalMagnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. … It is used as an antacid and mild laxative and has many nonmedicinal uses.
Mixtures: Cal-mag Plus K, Mn and Zn Caplets, Virt-PnDesogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]
Synonyms: 13-Ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-17-olCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors. … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Ataluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigational[label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568] … infections in adults.
Protein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETNeon
go.drugbank.com/drugs/DB11589ApprovedNeon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test. … It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth.